X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

American biopharmaceutical manufacturing: Fueling economic growth now and for years to come

By Nicole Longo  |    December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...   Read More

End of year Part D reading List

By Tom Wilbur  |    December 18, 2020
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

By Nicole Longo  |    December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...   Read More

Increasing diversity at investigator sites could increase minority participation in clinical trials

By Guest Contributor  |    December 17, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New report highlights biopharmaceutical industry’s commitment to D&I

By Abigail Lore  |    December 17, 2020
Today, PhRMA released a new report prepared by TEConomy Partners, LLC that provides insights into the efforts of biopharmaceutical companies to advance diversity & inclusion (D&I) in the...   Read More

Election insights: Voter priorities in the states

By Nick McGee  |    December 17, 2020
In the 2020 election, Americans nationwide cast their ballots with two major issues on their minds – the economy and coronavirus. Health care specific concerns centered on pre-existing conditions...   Read More

Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US

By Stephen J. Ubl  |    December 16, 2020
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections....   Read More

Insights from the election: Meeting voters where they are on health care

By Tom Wilbur  |    December 15, 2020
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter...   Read More

Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements

By Nicole Longo  |    December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...   Read More

Report: More than 1,300 medicines and vaccines in development to help fight cancer

By Andrew Powaleny  |    December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for...   Read More

New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

By Nicole Longo  |    December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...   Read More

Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Business

By Stephen J. Ubl  |    December 9, 2020
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.   Read More

Guest post: How COVID-19 underscores the importance of public confidence in vaccines

By Guest Contributor  |    December 7, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Guest Post: Bringing our best to the fight against COVID-19

By Guest Contributor  |    December 3, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Final rebate rule represents right way to change Medicare

By Tom Wilbur  |    December 1, 2020
As Washington policymakers look to make changes to Medicare and our health care system overall, there are right ways and wrong ways to address the challenges that seniors and patients face....   Read More

No matter how you look at it, the Most Favored Nation rule is bad policy

By Nicole Longo  |    December 1, 2020
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates